Morningstar

Vir Biotechnology Inc VIR

Morningstar Rating

Vir Biotechnology Appoints Jason O’Byrne as Chief Financial Officer

Business Wire Sep 10, 2024 12:05pm
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

Business Wire Sep 9, 2024 8:05pm
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031

GlobeNewswire Sep 4, 2024 12:30pm
Vir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Business Wire Aug 22, 2024 12:05pm
Vir Biotechnology to Cut 140 Jobs in Restructuring to Focus on Hepatitis Drug Development

Global News Select Aug 1, 2024 9:31pm
Vir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline Opportunities

Business Wire Aug 1, 2024 8:02pm
Vir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell Engagers

Business Wire Aug 1, 2024 8:01pm
Vir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024

Business Wire Jul 18, 2024 8:05pm
Vir Biotechnology's Tobevibart, Elebsiran Combo Gets FDA Fast Track Status for Chronic Hepatitis Delta

Global News Select Jun 26, 2024 12:51pm
Vir Biotechnology, GSK Terminate Collaboration on Flu

Global News Select Feb 22, 2024 9:57pm

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.